Categories: News

Verisante Share Consolidation Effective

VANCOUVER, BC / ACCESSWIRE / June 23, 2022 / Verisante Technology Inc. (the “Corporation”) (TSXV:VRS.H) announces that as of June 23, 2022, the common shares of the Corporation will commence trading on a post-Consolidation basis under the new ticker symbol VER.H on the NEX board of the TSX-V Exchange. the Corporation will undertake a consolidation (“Consolidation”) of its outstanding common shares on the basis of one (1) post-Consolidation Share for every ten (10) pre-Consolidation shares. The Consolidation has been approved by the directors of the Corporation, in accordance with the Articles of the Corporation.

As of the date of this news release, the Corporation has 98,615,888 common shares issued and outstanding. Following completion of the Consolidation, the Corporation is expected to have approximately 9,861,588 common shares issued and outstanding. The 15,354,182 common shares issuable upon TSX-V Exchange acceptance of the Corporation’s proposed shares for debt and private placement announced on June 6, 2022, will also be proportionally adjusted upon completion of the Consolidation. The Corporation has no preferred shares, warrants or options outstanding.

A letter of transmittal will be mailed to registered shareholders once the Consolidation has taken effect. The letter of transmittal contains instructions on how registered shareholders can exchange their share certificates evidencing their pre-Consolidation shares for new share certificates representing the number of post-Consolidation shares to which they are entitled.

Beneficial shareholders holding their shares through a brokerage may be subject to different procedures for obtaining their post-Consolidation shares. If shareholders have any questions in this regard, they are encouraged to contact their respective brokerage or intermediary.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Company Contact:

Thomas Braun, President & CEO
Verisante Technology, Inc.
Telephone: (604) 716-5133
Email: info@verisante.com

Forward Looking Statements:

This release contains forward-looking statements all of which statements are subject to market risks, and the possibility that the Corporation will not be able to achieve all of its stated goals. These statements are made based upon current expectations and actual results may differ from those projected due to a number of risks and uncertainties.

SOURCE: Verisante Technology, Inc.

View source version on accesswire.com:
https://www.accesswire.com/706229/Verisante-Share-Consolidation-Effective

Staff

Recent Posts

Unique Treatment for BPH, Chronic Prostatitis, Back Pain and Kidney Stones Was Unveiled at Arab Health 2024 by Ariana Adjani

* Efficacy, safety, and cost-effectiveness of Thermobalancing therapy and Dr Allen's Devices were showcased at…

20 hours ago

Financière de Tubize – Annual report 2023

FINANCIERE DE TUBIZE SA/NV Allée de la Recherche 60, 1070 Brussels Contact: investorrelations@financiere-tubize.be Annual Report…

2 days ago

ProSomnus Reschedules Fourth Quarter and Fiscal Year 2023 Investor and Business Update Call

PLEASANTON, Calif., March 15, 2024 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ: OSA) (the “Company”), the leading non-CPAP…

2 days ago

Ibogaine By David Dardashti Leverages Albert Einstein’s Corelation Between Photon Particles and Quantum Electrodynamics

Ibogaine By David Dardashti Revolutionizes Solar Energy Efficiency Through Radiation Generators Einstein A young and…

2 days ago

Psyence Biomedical Ltd. Receives Nasdaq Notifications Regarding Market Value of Listed Securities and Market Value of Publicly Held Shares

NEW YORK, March 15, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (the “Company”) (Nasdaq: PBM)…

2 days ago

NurExone’s Strategic Update: Submission of OTCQB Listing Application to Initiate US financial presence

TORONTO and HAIFA, Israel, March 15, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX)…

2 days ago